Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study.
Adult
Antibodies, Monoclonal, Humanized
/ adverse effects
Cohort Studies
Crohn Disease
/ diagnosis
Female
Gastrointestinal Agents
/ administration & dosage
Humans
Infant, Newborn
Inflammatory Bowel Diseases
/ diagnosis
Patient Safety
Pregnancy
Pregnancy Outcome
Pregnancy, High-Risk
Prognosis
Prospective Studies
Risk Assessment
Tumor Necrosis Factor-alpha
/ therapeutic use
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
pubmed:
29
3
2019
medline:
3
3
2020
entrez:
29
3
2019
Statut:
ppublish
Résumé
Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs' (VDZ) safety profile in pregnancy is not established. Data of 330 consecutive pregnancies with IBD was prospectively collected. Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn's disease patients who were all not naïve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy. Although further study is needed, VDZ appears of low risk during pregnancy.
Identifiants
pubmed: 30920987
doi: 10.14309/ajg.0000000000000186
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Gastrointestinal Agents
0
Tumor Necrosis Factor-alpha
0
vedolizumab
9RV78Q2002
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM